EPHA2 and central nervous system cancer: Targeting EphA2 represents an important goal in the development of recent anti-cancer drugs also in veterinary medicine, as shown by the attempt to evaluate the mechanism of Desanitib in the treatment of canine histiocytic sarcoma and the development of a cytotoxic compound that targets EphA2, EphA3, EphAB2, and interleukin 31 receptor A2 (IL31RA2) in canine high-grade gliomas (173, 174).